Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer:Current status in clinical trials
作者机构：Laboratory of Aging Research and Cancer Drug TargetState Key Laboratory of Biotherapy and Cancer CenterNational Clinical Research Center for GeriatricsWest China HospitalSichuan UniversityChengduSichuan610041China
出 版 物：《Genes & Diseases》 (基因与疾病（英文）)
年 卷 期：2023年第10卷第1期
页 面：76-88页
核心收录：
学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 0703[理学-化学] 100214[医学-肿瘤学] 10[医学]
基 金：This work is supported by the Key R&D Project of Sichuan Province,China(No.2020YFS0553) the National Science Fund for Excellent Young Scholars,China(No.32122052) the National Natural Science Foundation Regional Innovation and Development,China(No.U19A2003)
主 题：Clinical trials Molecular target therapy RAS-RAF-MEK-ERK signaling pathway
摘 要：Molecular target inhibitors have been regularly approved by Food and Drug Administration(FDA)for tumor treatment,and most of them intervene in tumor cell proliferation and *** RAS-RAF-MEK-ERK pathway is a conserved signaling pathway that plays vital roles in cell proliferation,survival,and *** aberrant activation of the RAS-RAF-MEK-ERK signaling pathway induces *** 33%of tumors harbor RAS mutations,while 8%of tumors are driven by RAF *** efforts have been dedicated to targeting the signaling pathway for cancer treatment in the past *** this review,we summarized the development of inhibitors targeting the RAS-RAF-MEK-ERK pathway with an emphasis on those used in clinical ***,we discussed the potential combinations of inhibitors that target the RAS-RAF-MEK-ERK signaling pathway and other signaling *** inhibitors targeting the RAS-RAF-MEK-ERK pathway have essentially modified the therapeutic strategy against various cancers and deserve more attention in the current cancerresearchandtreatment.
维普期刊数据库